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Abstract
Europrise is a Network of Excellence supported by the European Commission within the 6th Framework
programme from 2007 to 2012. The Network has involved over 50 institutions from 13 European countries together
with 3 industrial partners and 6 African countries. The Network encompasses an integrated program of research,
training, dissemination and advocacy within the field of HIV vaccines and microbicides. A central and timely theme
of the Network is the development of the unique concept of co-usage of vaccines and microbicides. Training of
PhD students has been a major task, and some of these post-graduate students have here summarized novel ideas
emanating from presentations at the last annual Europrise meeting in Prague. The latest data and ideas concerning
HIV vaccine and microbicide studies are included in this review; these studies are so recent that the majority have
yet to be published. Data were presented and discussed concerning novel immunisation strategies; microbicides
and PrEP (alone and in combination with vaccines); mucosal transmission of HIV/SIV; mucosal vaccination; novel
adjuvants; neutralizing antibodies; innate immune responses; HIV/SIV pathogenesis and disease progression; new
methods and reagents. These – necessarily overlapping topics - are comprehensively summarised by the Europrise
students in the context of other recent exciting data.
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Introduction
The 2011 Network Annual Conference of Europrise was
held from 14th to 17th November in Prague, the Czech Re-
public, and was attended by 100 partners from 31 European
institutions, two members of the advisory board, ten
affiliated partners and eight invited guests. Scientific data
from earlier meetings were summarized previously [1,2].
New important data from oral and poster presentations
were discussed by all collaborators at the conference and
are summarised here by our PhD students. All participants
at the meeting were greatly encouraged and excited by posi-
tive data from recent microbicide and vaccine trials, in the
context of which the meeting’s eight sessions dealt with the
latest European clinical trials of pre-exposure prophylaxis
(PrEP) with vaccines, microbicides and drugs in both man
and animal models, using conventional and novel strategies,
and aimed at inducing measureable innate and specific im-
mune responses, both cellular and humoral.
One of the outstanding features of the Europrise Net-
work of Excellence has been a work package dedicated
to a PhD student training programme. In this context,
young researchers have made exchange visits between
laboratories of the Network and have attended dedicated
workshops and conferences. During Europrise’s lifetime,
35/64 students from 30 laboratories have completed
their postgraduate studies, 20 of these students were dir-
ectly funded by the Europrise programme.
HIV vaccines
Several strategies to hasten the development of an effect-
ive HIV vaccine were presented. These strategies
included the production of novel vector platforms, the
identification of potent adjuvants, the development of
delivery devices and novel challenge models. A descrip-
tion of these novel immunization strategies is given, and
their implications are discussed.
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Clinical trials
Immunological correlates of protection
The RV144 Phase III trial is the only trial in which the clin-
ical efficacy, estimated at 31%, of an HIV vaccine has been
demonstrated in man [3]. This prime-boost strategy was an
attempt to combine an avipox recombinant vector expres-
sing human immunodeficiency virus type 1 (HIV-1) Gag,
Pro, with a bivalent gp120 protein boost (AIDSVAX B/E)
[3]. This trial involved 16,400 Thai subjects. The modest ef-
ficacy signal in the RV144 trial has enabled a formal search
for correlates of risk (increased or decreased risk of infec-
tion within the vaccinated cohort), involving a pre-specified
plan of six primary and a large number of exploratory ana-
lyses. Analyses compare immune responses in vaccinated
infected persons with those in vaccinated, uninfected per-
sons [4,5]. Jerome Kim from the Walter Reed Army Insti-
tute of Research presented data showing that 2 of the 6
pre-specified primary analyses, corrected for multiple com-
parisons, were identified as correlates of risk that may be
used as hypotheses for future testing. The first was a meas-
ure of the magnitude and breadth of anti-HIV Env IgA
binding that was directly correlated with infection (RR 1.54;
p= 0.027), although no enhancement of infection was seen
compared to the placebo groups. The second was an indir-
ect correlation between IgG binding to the V1V2 loop of
gp120 and a 43% reduction in the HIV infection rate (RR
0.57 p=0.015). Sieve analyses of breakthrough viruses, as
well as antibodies from vaccinated uninfected volunteers,
suggest that antibodies against the V2 loop may be asso-
ciated with escape mutations in breakthrough viruses.
Taken together, these findings support the original modest
efficacy of the RV144 trial, and suggest hypotheses that can
be tested in future animal challenge experiments [4].
Scientists from IDIBAPS (Institut d´Investigacions Bio-
mèdiques August Pi in Sunyer and University of Barcelona)
reported the results of the phase I clinical trial RisVac02
[6]. The study’s purpose was to evaluate the safety and im-
munogenicity of a modified vaccinia virus Ankara (MVA)
vector expressing monomeric gp120 and the fused Gag-
Pol-Nef polyprotein of clade B (MVA-B). Thirty HIV-1
negative volunteers were given three intramuscular injec-
tions of MVA-B or placebo at weeks 0, 4 and 16 and fol-
lowed for one year. The vaccine was safe and well
tolerated: a number of adverse events were reported but
they either were not related to the vaccination or were in-
jection site reactions. The majority of the individuals
(75 %) exhibited broad and polyfunctional CD8+ and CD4
+ T-cell responses, especially directed against Env.
Responses were durable, being detectable during the entire
follow-up period, and were mainly found within the ef-
fector memory T-cell subset. Antibody responses to Env
were induced in almost all the vaccinees and HIV neutral-
izing activity against BX08, tier 1, was observed in 33% of
the volunteers [7]. Taken together, these findings suggest
MVA-B as a promising HIV-1 vaccine candidate. Further
studies are needed to assess the boosting effects of recom-
binant proteins. These results reflect the wider recognition
that pox-based vectors represent promising components of
potential HIV vaccines, the basis for the formation of the
Pox Protein Public Private Partnership (P5, by Sanofi and
Novartis, see AVAC.org) initiated with the objective of
building on these and other important results to develop
further pox-protein vaccines [8].
Another Europrise study (HIVIS) was reported which has
advanced prophylactic vaccination by priming with multi-
gene DNA, followed by MVA-CMDR of the type CRF A_E;
thereafter the intention is to boost with the Env glycopro-
tein subtype C, the novel concept of prime-boost-boost.
Consecutive development of cellular and then antibody
responses to many HIV-1 subtypes was described [1,2,9]. A
serological study to determine the breadth and magnitude
of antibody responses to inserts in DNA, viral vector or
protein components of the HIVIS vaccine is underway, sup-
ported by an innovation grant from Europrise.
Susan Barnett from Novartis described the planned de-
velopment within the context of the Pox Protein Public Pri-
vate Partnership (P5) of a proof-of-concept trial in South
Africa, building on the findings of the RV144 trial but using
clade C inserts and protein (gp120). The aim is to develop
new envelope proteins and reagents for the subtype C
HIV-1 epidemic. A pox virus (ALVAC) prime developed by
Sanofi-Pasteur will contain the highly immunogenic ZM96
gp120–TM [10] and the boost will contain two subtype C
gp120 proteins (TV-1 and 1086 C) formulated with the
licensed potent vaccine adjuvant MF59. Use of gp120
monomers instead of trimers has been prioritised in order
to make comparisons with data from the RV144 trial [3].
Data were presented on a novel T-cell immunogen,
termed HIVconsv, designed by Tomas Hanke and Andrew
McMichael (University of Oxford) to address HIV-1 diver-
sity. Fourteen of the most conserved regions of Gag, Pol,
Vif and Env have been assembled into one synthetic DNA
construct. To ensure coverage of the virus diversity, each
consensus fragment was derived from different HIV-1
clades [11]. The sequence coding for the HIVconsv immu-
nogen has been inserted into plasmid DNA, MVA and
into non-replicating adenovirus of chimpanzee origin
ChAdV-63 [12]. The three candidate vaccines adminis-
tered in combination were highly immunogenic in mice
and macaques. A phase I/IIA clinical trial (HIV-CORE002)
is currently underway to evaluate their safety and im-
munogenicity in healthy adults. Preliminary results suggest
that the HIVconsv-based vaccines are safe and able to in-
duce T-cell responses.
Studies of attenuated viruses and virus-like particles
In order to be useful as immunogens, inactivated virions
should preserve their immunogenicity and be safe for the
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patient. Plana and collaborators (Hospital Clinic-IDIBAPS,
Barcelona) investigated the immunogenicity of a reverse
transcriptase (RT) defective virion (NL4-3/ΔRT). Using
stored lymphocytes from asymptomatic HIV-positive
patients, they showed that NL4-3/ΔRT viruses induced T-
cell responses in vitro in 56% of the individuals tested,
while only 24% of them were responsive to the NL4-3 wild
type virions inactivated with aldrithiol-2 [13]. The im-
mune responses were significantly stronger against the
RT-defective viral particles and included both CD4+ and
CD8+ restricted responses. The results encourage further
exploration of NL4-3/ΔRT viruses as additional reagents
for screening HIV-1 specific responses in HIV seropositive
individuals and vaccinees.
Further interrogation of the mechanisms of protection
provided by attenuated viruses was reported in non-human
primate (NHP) studies. Martin Cranage presented work
performed by Maria Manoussaka as part of a collaboration
with Neil Almond’s team at NIBSC and Ben Berkhout’s
team at AMC, demonstrating that infection of macaques
with SIVmac239Δnef or a doxycycline (dox)-dependent
conditional replication variant of SIVmac239Δnef, desig-
nated SIVrtTA, increases the proportion of circulating T
effector memory (Tem) (CD28-CD95+CCR7-) cells with
a concomitant reduction of T central memory (Tcm)
(CD28+CD95+CCR7+) CD4+ and CD8+ cells only
under replication-permissive conditions. Similar changes
following infection were found in gut mucosal-homing
(α4+ β7+ and β7+) T-cells but the changes were also
maintained after doxycycline withdrawal. Also, global
phenotype data of polyfunctionality of SIV-specific T-cells
in the periphery and in the gut of the animals were pre-
sented. These data may contribute to our understanding
of the mechanisms of resistance to superinfection.
The mechanisms behind protection induced by live atte-
nuated SIV are still unclear. One of the theories is that the
failure to superinfect ‘immunized’ monkeys is due to com-
petition for available target cells rather than immune con-
trol. To uncouple replication from immune response,
Oliver Hohn (Robert Koch Institute) produced a 181 bp
nef-deletion version of Klaus Überla’s SIVmac RT-SHIV
that expresses the HIV reverse transcriptase. Unlike wild-
type SIVmac, this virus was highly susceptible to the anti-
viral compound nevirapine. Eight rhesus macaques were
infected with nef RT-SHIV; after allowing the immune re-
sponse to develop for 40 weeks, four were given a daily
dose of nevirapine (together with four 'unvaccinated' con-
trol animals). At 48 weeks, all 16 monkeys (vaccinated and
unvaccinated, with and without nevirapine treatment) were
challenged with wild-type SIVmac239. During the vaccin-
ation phase, all animals developed virus specific B- and T-
cells. Peak viral load in vaccinated macaques after chal-
lenge was 2-3 orders lower than in control animals, and by
week 10 all vaccinated animals were virus negative. Most
importantly, there was no evidence that suppressing virus
replication by nevirapine diminished the ability of the
immunized macaques to resist infection by the challenge
virus. These exciting results led to the conclusion that the
suppression of virus replication in vivo was not the result
of competition for infectable targeT-cells through active
replication of the vaccine virus.
An alternative approach to attenuated viruses is the
development of virus-like particles (VLP). This proved
to be successful for the group of Buonaguro et al (Natl.
Cancer Institute Pascale, Naples) which used the insect
baculovirus system to produce VLP. These VLP vaccines,
which are non-infectious and safe, show promise with or
without HIV DNA priming [14].
Preclinical challenge models
Anti-viral CD8+ T-cell responses are commonly studied
mechanisms, thought to play a protective role during HIV-
1 disease progression. Several presentations at the Europrise
meeting focused on novel T-cell vaccines in NHP models,
with a low-dose repeated rectal challenge. Such models
may give us better insight into the potential clinical utility
of vaccines following a physiologically relevant challenge.
Neil Almond from NIBSC presented data on a novel vac-
cine designed to promote potent T-cell responses to mul-
tiple epitopes, based on a strategy designed and developed
by Steve Patterson (Imperial College). Mauritian cynomol-
gus macaques were immunized intra-dermally with recom-
binant DNA and boosted with a recombinant non-
replicating Adenovirus expressing wild type SIV full length
Gag, with an ubiquitin sequence fused to the amino
terminus, or a fragmented SIV Gag gene with an ubiquitin
sequence fused to the amino terminus of each fragment.
Animals were challenged repeatedly intra-rectally with
low-dose SIVmac251. No difference in protection was seen
between the three groups of vaccinated animals receiving
the fragmented or full length SIV Gag. However, there was
evidence that vaccinated macaques were less likely to ac-
quire infection compared with naive challenge controls,
though the effect did not quite achieve significance at the
5% level. These data suggest that modification of SIV Gag
based antigens by either ubiquitin fusion strategies or frag-
mentation provide no significant advantage to to a vaccine
that provided mildly beneficial effect. Additional studies
are underway to compare the immunogenicity of these dif-
ferent vaccines as well as alternative routes of vaccination.
In a further study, reported by Christiane Stahl-Hennig
from the German Primate Center, rhesus macaques were
subcutaneously primed with single-cycle immunodeficiency
virus (SCIV), followed by either an oral spray application
or an intramuscular injection of either a recombinant
Adenovirus (rAd) expressing SIV Gag/Pol and Env, or a re-
combinant fowlpox virus (rFPV) expressing SIV Gag and
Env. Animals were then repeatedly challenged intrarectally
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with low-dose SIVmac251. The vaccination regimen with
immunization with oral rFPV followed by the systemic rAd
was superior to the reverse strategy, as shown by the
delayed acquisition of highly pathogenic SIV and reduced
viral load post infection.
Klaus Uberla (University of Bochum) presented a strategy
designed to direct antigens to dendritic cells (DC) and en-
hance T-cell antigen presentation, using a novel modality
where Gag p27 is fused with a single-chain antibody that is
specific for the DC-restricted antigen uptake receptor,
DEC205. Macaques received the vaccine intramuscularly and
were later boosted with virus-like particles to induce a
humoral immune response. Somewhat counter-intuitive
results showed that animals vaccinated with control anti-
bodies coupled to Gag p27 made stronger IFNγ CD4 and
CD8 T-cell responses than animals vaccinated with p27 fused
to the DEC205 antibodies. After repeated low-dose rectal
challenges there was a trend to faster infection in the group
with the higher IFNγ responses and animals with a high
IFNγ response were infected significantly faster than poor
responders. These findings raise questions as to whether
vaccine-induced immune responses may under some cir-
cumstances lead to increased risk of acquiring SIV infection.
The role of APOBEC 3 G (apolipoprotein B mRNA edit-
ing cytokine deaminase) and AID (activation induced deami-
nase), innately expressed by B-cells, in protection against
SHIV infection was discussed by Thomas Lehner (GKT,
London). Macaques were immunized with recombinant
MHC constructs linked to HIV/SIV antigens, HSP70 and
dextran. Results showed significant upregulation of AID in
B-cells and upregulation of APOBEC 3G in CD27+ memory
B-cells and CD4+ effector memory T-cells in immunized
animals. Following challenge with SHIV SF162.P4 viral load
was inversely correlated with AID in B-cells and APOBEC
3 G in B- and T-cells of infected animals, suggesting that the
MHC/SHIV vaccine construct stimulated parallel responses
by the two deaminases that might be involved in pre-entry
and post-entry control of SHIV replication [15].
In a SHIV-based model, presented by Mark Page
(NIBSC), macaques were vaccinated with an HIV-1
W61D rgp120 envelope construct and challenged intra-
venously with heterologous viruses. Neutralizing anti-
bodies were detected against rgp120 homologous to the
vaccine, but only limited neutralization was seen against
the two heterologous SHIV challenge strains. Protection
against infection correlated with T-cell proliferative
responses specific for peptides present in HIV-1 W61D
rgp120. However, transfer of serum from the vaccinated
animals with measureable titres of neutralizing anti-
bodies to naive animals did not confer protection, high-
lighting a putative important role of CD4+ T-cells in
protection from HIV-1 infection.
Measles vaccine vectors have been reported as a novel
strategy with a potential to deliver heterologous antigens
into the antigen-processing pathways, promoting strong
CD4+ and CD8+T-cell responses [16]. In this context,
Richard Stebbings (NIBSC) reported an immunogenicity
study to characterize cellular immune responses induced
by a recombinant measles vector carrying inserts for
HIV-1 Clade C Gag, RT and Nef (MV1-F4) in cynomol-
gus macaques. A significant increase in the T-cell
responses to the HIV insert was detected in animals
immunized with both low and high dose MV1-F4. Of
interest, the addition of a second boost further increased
CD4+ T-cell responses in both groups despite the pres-
ence of high titres of measles neutralising antibodies, al-
though this was not the case for CD8+ T-cell responses.
Novel immunization strategies
A major hurdle in the development of HIV-1 vaccines is
the construction of immunogens capable of inducing
antibodies that can broadly neutralize HIV-1. In order to
prevent initial infection of host cells or limit early events
of viral dissemination, neutralizing antibodies must tar-
get the surface envelope glycoproteins of many human
immunodeficiency viruses, which are highly variable in
sequence and structure [17]. Indeed, as principal viral
target of neutralizing antibodies, the HIV-1 viral spike
has evolved to evade antibody-mediated neutralization.
Anna-Lena Spetz (Karolinska Institutet) presented data
on a new vaccination strategy under development to
overcome the high diversity of HIV-1 by inducing im-
mune responses towards relatively conserved regions of
gp120 and gp41. Since the variable epitopes of Env are
generally more immunogenic than the conserved parts,
immune responses are preferentially induced to variable
regions. In order to focus B-cell responses to conserved
neutralizing epitopes of Env, Spetz et al. applied a heter-
ologous prime-boost strategy consisting of a DNA prime
comprising a mix of three HIV-1 Env clade B gp140
constructs, followed by a boosting with a very different
Env trimeric gp140 protein, administered to rabbits.
They hypothesized that by mixing three different envel-
opes during the DNA prime, the concentration of anti-
gen derived from the conserved regions would be higher
than that from the more variable regions. Boosting with
a different Env protein as compared to the DNA prime
would further increase the likelihood of targeting con-
stant regions of Env. The results showed that high titres
of heterologous HIV-1 neutralizing antibodies were
induced against Tier 1 viruses in the TZM-Bl assay and
against Tier 2 viruses in the A3R5.7 assay. These data
support further exploration of such heterologous regi-
mens for induction of broadly neutralizing antibodies.
Previous work performed by Andrea Cara at the Instituto
Superiore di Sanità has shown that integrase defective len-
tiviral vectors (IDLV) expressing HIV-1 gp120 can be used
for the induction of polyfunctional CD8+ T-cell responses
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and gp120-specific serum antibodies in mice [18]. In
addition, ex vivo transduction of human macrophages and
DC with IDLV expressing the influenza matrix protein M1
induced expansion of antigen-specific polyfunctional CD8+
T-cells. At the EUROPRISE meeting, Cara presented new
data demonstrating that the addition of the SIV VpX pro-
tein to IDLV vectors enhances transduction efficiency in
human and simian DC, thereby improving antigen presen-
tation. Recent studies have demonstrated that host cell
SAMHD1 acts as an HIV-1 restriction factor by inhibiting
viral DNA synthesis [19]. The SIV VpX protein targets
molecules in SAMHD1 to the proteasome for degrad-
ation, thereby enabling viral replication. Thus, by inhibit-
ing SAMHD1-mediated restriction of viral replication, the
SIV VpX protein may enhance the transduction efficiency
of IDLV in human and simian DCs, thereby admitting the
use of lower doses of vaccine, which improves the safety
profiles for IDLV. Other studies of retroviral vector use
were performed by Pepe Alcami et al. from Instituto de
Salud Carlos III, Madrid. They demonstrated that RT-
defective virions acted as effective immunogens for T-cells.
Rico Blochmann, a young investigator from the Robert
Koch Institute, described the development of novel rep-
licating foamy virus vectors capable of prolonged antigen
presentation. Infection with low-level replicating retro-
viral foamy virus is often symptom-free, and the viral
particle could be used as an alternative vector in an HIV
vaccine construct. A foamy hybrid virus has already been
tested in hamsters, with rapid responses to encoded pro-
teins, and a vector for rhesus macaques has been devel-
oped. Two reading frames of the viral genome were
successfully removed without affecting viral replication
in the macaque model. A viral vector expressing GFP
and a variety of HIV CTL epitopes have been developed
and are being tested in vitro.
A new strategy for genetic HIV vaccination based on
heterologous prime-boost regimes using different vectors
and viral genes was presented by Marc Reudelsterz from
the Robert Koch Institute. This approach, designed to
avoid a decrease in vaccine efficacy following repeated vac-
cination using the same vector, was adopted in parallel for
HIV- and SIV vaccines. Codon-optimised constructs (rev-
nef-tat-gag and pol) were used to prepare vaccine vectors
based on plasmid DNA, recombinant adeno-associated
virus (rAAV) and recombinant adenovirus 5 (rAd5). The
magnitude and breadth of T-cell responses were increased
following heterologous triple-immunization of mice with
DNA-, rAd- and rAAV-based immunogens, especially
against the Pol and Gag gene products of HIV and SIV.
An innovative method for HIV vaccine delivery was
presented by the EUROPRISE student Charlotte Pollard
from the Institute of Tropical Medicine in Belgium. She
has delivered Gag mRNA complexed to DOTAP/DOPE,
a cationic lipid used for transfection subcutaneously in
mice to be processed and presented by immune cells
(unpublished). In an in vivo killing assay, Gag-expressing
splenocytes were shown to be selectively killed. When
combined with a Gag mRNA - p24 protein boost, both
IgG1 and IgG2 antibodies were detected, as well as Th1
and Th2 responses. In addition, inflammatory DCs were
detected in lymph nodes one day after vaccination. Other
means to enhance transfection consist of electroporation
of DNA- or RNA-based antigens significantly raises im-
munogenicity of the expressed protein [20].
Microbicides & Pre-exposure prophylaxis (PrEP)
Clinical studies
Development of an effective microbicide against HIV-1
continues to be a major target for the HIV community.
The microbicide session of the Europrise meeting gave a
comprehensive update on preclinical and clinical studies
of novel potential microbicides.
Ian McGowan (University of Pittsburgh) discussed
microbicide development in the context of the encouraging
CAPRISA 004 microbicide efficacy trial [21] and provided
a comprehensive review of the NIH-funded Microbicide
Trials Network's clinical trial portfolio (see Figure 1).
Results from the CAPRISA 004 trial of tenofovir 1%
gel and other trials of oral pre-exposure prophylaxis
(PrEP) of tenofovir support the topical and oral use of
antiretrovirals for prevention of HIV infection. Differ-
ences in protection rates across these clinical trials may
be explained by a variety of factors, including the hetero-
geneity of study populations, the route and frequency of
dosing, as well as differential levels of tenofovir metabo-
lites in the vagina compared to the rectum after oral
dosing, and much higher levels of active drug in the
genital tract after topical antiretroviral treatment. Al-
though the precise threshold of drug required for pro-
tection has yet to be determined, it was shown that
topical administration achieved the highest levels of drug
in the genital tract and low systemic levels.
A major driver of overall effectiveness of either micro-
bicides or oral PrEP was adherence; this should be taken
into account in the development of future trials and
microbicide delivery strategies. Besides improving the
methods for collecting information on product use, pri-
ority should now be given to establishing the safety of
tenofovir gel in pregnancy, adolescence, and rectal use.
Tenofovir as pre-exposure prophylaxis (PrEP) has been
shown to significantly reduce HIV incidence, alone or in
combination with emtricitabine. Whereas the CAPRISA
microbicide trial observed a 39% reduction in HIV ac-
quisition with a ‘before and after’ sex schedule of tenofo-
vir vaginal gel [21] and the iPREX PrEP trial observed a
44% reduction with daily oral Truvada (tenofovir/emtri-
citabine), the FEM-PrEP trial showed no effect for Tru-
vada in women [22]. In May 2011, several researchers
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came together in a EUROPRISE workshop to better under-
stand how adherence and biology explained the diverse ef-
fectiveness in these three trials. The most likely biological
hypothesis was that when drug was administered orally,
the level of active drug in the cervico-vaginal tissue was
influenced by endogenous and exogenous female hor-
mones. This question is now being investigated in a clinical
trial. The promise of antiretroviral-based prevention also
inspired a satellite meeting co-organised by AVAC, EATG
and the Forum for Collaborative HIV Research during the
6th IAS Conference on HIV Pathogenesis, Treatment and
Prevention (July 2011 in Rome). This meeting concluded
that it was time for the development of a multi-stakeholder
consensus statement on the need to expand efforts to use
antiretroviral-based combination prevention to achieve
community-level control of HIV infection. Today we have
far more options for preventing HIV than when
EUROPRISE started (Figure 1) but considerably more re-
search will be required before we know how best to deploy
these alone and in combination in public health programmes.
New components for a microbicide
Neutralizing antibodies have been considered as novel
microbicide candidates, since antibodies directed
against conserved regions of HIV-1 proteins may inhibit
HIV entry into host cells. Llama heavy-chain antibody
fragments (VHH) are a class of molecules recently
described as potent cross-clade HIV-1 entry inhibitors.
Laura McCoy et al. (University College of London)
showed that VHH antibodies isolated from libraries
derived from llamas immunized with recombinant gp120
or trimeric gp140, have neutralizing activity against several
strains of HIV-1. In particular, one potential candidate
neutralizing antibody, J3, was identified on the basis of its
capacity to neutralize the majority of HIV-1 pseudoviruses
tested. Moreover, the importance of llama antibodies was
underlined by their characteristic of being chemically and
thermally stable and by their low production cost. Feasibil-
ity studies are now needed to determine the developmental
pathways needed to bring this approach to clinical trials.
The EU funded Pharma-Planta Integrated Project was
presented by Julian Ma (St George´s, University of Lon-
don) as a potential platform for large-scale production of
anti-HIV neutralizing antibodies produced in transgenic
tobacco plants. He stressed the fact that this approach
represents a new affordable manufacturing platform for
proteins and microbicide combinations. Indeed, following
cGMP approval for production of antibodies in plants, a
clinical trial application has been approved, allowing a
Phase I clinical trial to start. The results of the trial are
anticipated to be available in late 2012.
Reverse transcriptase (RT) inhibitors might also form im-
portant components of an effective microbicide, as demon-
strated by the CAPRISA 004 trial of tenofovir gel. TMC-
120, a Non-nucleoside Reverse Transcriptase Inhibitor
(NNRTI), is currently being evaluated in a phase III effi-
cacy trial, while other NNRTIs are being tested in preclin-
ical trials. Susan Fetherston et al. (Queen’s University,
Belfast) presented data on MC1220, another NNRTI evalu-
ated in a non-human primate challenge study. MC1220
has previously been demonstrated to have potent anti-HIV
activity in vitro and partial efficacy when formulated as a
liposomal gel in macaques exposed to RT-SHIV [23].
Dr Fetherston presented results on the use of MC1220-
Figure 1 Reduction of HIV transmission by selected biological or drug interventions. Modified from Shattock et al [34] and expanded by us.
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loaded vaginal rings in macaques and showed the pres-
ence of detectable drug levels in both vaginal fluid and
plasma during the entire period of ring-placement. Drug
release from vaginal rings was also demonstrated in
in vitro experiments using simulated vaginal fluid. After
the PK study (days 0-28), the same macaques were
included in a challenge study. A one-week washout period
was followed by placement of either a placebo (n= 4) or a
400 mg MC1220 ring (n= 6) on Day 35. Macaques were
subsequently challenged with vaginally-administered RT-
SHIV162P3 once a week for four weeks, on days 42, 49,
56 and 63. In the placebo arm, 1 of 4 macaques was
infected within two weeks of placebo ring placement and
following a single vaginal challenge; the remaining three
macaques in the placebo arm were infected within four
weeks of ring placement and following three challenges.
The active ring provided a greater degree of protection,
with one macaque infected by week 4, another by week 5,
and a further two by week 6. At the end of six weeks, and
following 4 challenges, 2/6 macaques remained unin-
fected. These results make MC1220 a promising compound
for further development as a topical microbicide, and vagi-
nal rings a promising device for delivering microbicides.
The ultimate goal for prevention is to increase the effi-
cacy of individual strategies, providing a comprehensive
blockade to HIV infection. Studies are underway to de-
termine whether the potential protection delivered by
microbicides could be increased by combining them
with vaccination. Such a concept is at the heart of the
Europrise Network of Excellence. Roger Le Grand et al.
(CEA, Paris) presented preliminary data on a study per-
formed in Cynomologus macaques where animals were
immunized intranasally with trimeric gp140 subtype B
and C proteins, followed by two intramuscular boosting
immunizations with the same two proteins formulated
in MF59. Animals were then challenged intravaginally in
the presence or absence of 1% Tenofovir microbicide
gel. The immunization schedule induced good systemic
and vaginal immunity as measured by specific IgA and
IgG levels, and presence of neutralizing antibody to tier
1 viruses in the serum but not in the vaginal secretions.
The combination of vaccine with microbicide showed
enhanced protection against SHIV challenge when com-
pared to animals treated with microbicide alone; both
microbicide alone and the combination provided signifi-
cant protection against low-dose repeat viral challenge
when compared to naïve challenged animals. Ongoing
studies will assess the efficacy of the vaccine alone.
Mucosa and HIV-1/SIV transmission
Mucosal biology and viral infection
The potential influence of the human vaginal micro-
environment on HIV transmission was addressed by
Jordan Kyongo et al. (Institute of Tropical Medicine,
Antwerp, Belgium). The presence of soluble immunomo-
dulatory factors was evaluated in the genital fluids of a co-
hort of healthy Caucasian women. It was shown that levels
of IL-1α, IL-1ra, IP-10, MIP-1b and the antimicrobial pro-
tein β-defensin fluctuated during different phases of the
menstrual cycle. Such fluctuation may modulate suscepti-
bility to HIV infection, potentially an important consider-
ation when designing vaginal intervention strategies.
In contrast, Kevin Mendonca, a student from the Univer-
sity of Siena, demonstrated the importance of the seminal
compound spermine in down-regulating TLR expression
on vaginal epithelia cells. He raised the possibility that as
activation of some TLRs, for example TLR-3, significantly
reduces viral infection, the action of spermine might be a
factor that influences male-to-female transmission of HIV
through dampening of innate antiviral responses. However,
the in vivo relevance of these findings requires further
investigation.
Mariangela Cavarelli from San Raffaele Scientific Insti-
tute in Milan discussed studies concerning the susceptibil-
ity of dendritic cells and CD4+ T lymphocytes to HIV-1
infection using an in vitro model of intestinal mucosa.
The influence of epithelial cells on HIV-1 infection of DCs
and CD4+ T-cells was investigated to provide a better
understanding of virus transmission events at the intes-
tinal mucosa. Supernatants from the epithelial cell line
Caco-2 were used to condition monocyte-derived DCs
and CD4+ T-cells, and the expression of HIV co-receptors
as well as HIV infection were analyzed. The infectibility of
DCs with R5 or X4 virus was altered in terms of a reduced
integration of viral genome. Both R5 and X4 viruses
infected both conditioned and non-conditioned CD4+ T-
cells better than DCs, although conditioning did not alter
CD4+ T-cell susceptibility to HIV-1 infection.
Several studies have shown that infected seminal leuco-
cytes can cross intact vaginal epithelia to reach the sub-
mucosa and the draining inguinal lymph nodes. In this
way, cell-associated virus may still establish infection by es-
caping the high microbicide concentrations in the vaginal
lumen. However, virus budding from these migrating leu-
cocytes could be attenuated by prior vaginal drug exposure.
Katrijn Grupping and Philippe Selhorst (ITM, Antwerp,
Belgium) reported that, in contrast to other antiretrovirals,
pre-treatment of HIV-infected PBMCs with M48U1 CD4-
mimetic results in a dramatic and prolonged reduction of
virion infectivity. This ‘memory effect’ is related to gp120
shedding from membrane-embedded HIV envelope pro-
teins. Inclusion of M48U1 in topical microbicides may
therefore help to reduce the risk of systemic infection by
infected cells.
Another EUROPRISE-supported student, Kelly da Costa
from St George’s Hospital in London, presented research
on in vitro infection of virus-naïve macaque colorectal
explants. She compared SIV superinfection of explants
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taken from SIV-infected macaques with either disease pro-
gressor or non-progressor phenotype. Colorectal tissues
from progressors did not show extra virus production after
superinfection challenge, whereas the pattern after chal-
lenge of tissues from LTNPs was more variable. While both
IgG and IgA total immunoglobulins were secreted from
the explanted cultures of SIV-infected macaques, only IgG
gp130-specific antibody was detected.
Elisa Saba from the San Raffaele Scientific Institute
presented data concerning factors affecting HIV-1 per-
missibility in a human cervical explant model. The most
prominent CD4+ T-cell type in the mucosa was of the
effector memory phenotype, and 50% and 80% of the
cells expressed CCR5 and CXCR4, respectively. R5 virus
efficiently infected the explants over time, while X4 only
infected 4/27 donors, despite the high levels of CD4 and
CXCR4 in the tissue. Saba also showed that the most
permissive donors had high progesterone blood levels,
which is in agreement with the literature, suggesting that
women on contraceptive pills containing progesterone
may be more easily infected than menopausal women.
These data support the use of tissue explant models to
further characterize factors of importance for the sexual
transmission of HIV.
Mucosal vaccination
Given that most HIV-1 transmissions occur during sex-
ual exposure of the genito/rectal mucosa, an ideal HIV-1
vaccine candidate should induce protective antibody
responses at the mucosal surfaces [24]. Although some
studies have shown that systemic delivery of HIV-1 vac-
cines can induce HIV-specific immune responses at the
mucosa [25,26], findings in mouse models indicate that
systemic delivery of HIV-1 vaccines can compromise the
quality or avidity of the HIV-specific immune responses
at mucosal sites [27].
Paul McKay (Imperial College in London) and co-
workers from Queens University (Belfast) have developed
a novel antigen delivery device to induce antigen-specific
immune responses directly at the vaginal mucosa. A sili-
cone elastomer ring carrier was used to deliver recombin-
ant gp140 antigen adjuvanted with a resiquimod (R848), a
TLR 7/8 agonist, into the vaginal cavity of sheep. Antibody
responses in sheep receiving only the ring devices were
compared to antibody responses in sheep primed intra-
muscularly with gp140 and R848 followed by insertion of
the antigen loaded rings. Results showed that both sys-
temic and vaginal priming induced antigen-specific IgG
and IgA responses in serum and vaginal fluid, with the
levels of IgA being 30-fold higher at the mucosal surfaces
than in serum. It was observed that intramuscular injec-
tion did not prime for the development of a mucosal IgA
response. Taken together, these data favour the use of this
novel ring device for the induction of antigen-specific sys-
temic and mucosal humoral immune responses.
Linda Klavinskis (Kings College, London) described an
alternative route of immunization designed to induce
mucosal cellular responses. Air-dried dissolvable micro-
needle arrays were developed to specifically target
dendritic cells in the skin, thereby enhancing antigen
presentation. Microneedle delivery of a rAd5 vector
encoding HIV-1 Gag induced antigen-specific CD4+ and
CD8+ T-cell responses in mice, and these responses
were as efficient as those induced by subcutaneous or
intradermal vaccination. Importantly, the use of this
micro-needle array device on the skin allowed the induc-
tion of Gag-specific CTL responses in the female genital
mucosa. Experiments using transgenic mice with
dendritic cells expressing langerin-DTReGFP or CD11c-
DTReGFP, demonstrated that conventional CD11chigh
dermal DCs, but not epidermal Langerhans cells are
required for the induction of CD8+ T-cell responses by
micro-needle array delivery.
The impact of intranasal immunization on the distribu-
tion of antigen-loaded antigen-presenting cells (APCs)
and of primed antigen-specific T-cells was studied by
Medaglini et al. (University of Siena). Nasal immunization
elicited primed T-cells not only in draining lymph nodes
but also in non-draining lymphoid sites. They showed,
through the use of Fingolimod, a drug that causes
lymphocyte sequestration within lymph nodes, that the
presence of primed T-cells at distal lymph nodes was due
to migration of locally primed T-cells. In contrast to
primed T-cells, antigen-loaded APCs could only be
detected in the draining mediastinal lymph nodes, and no
antigen-loaded APCs were observed in distal lymph
nodes. T-cell entry into iliac lymph nodes was found to be
CD62L dependent, while CD62L and α4β7 were
responsible for homing to the mesenteric lymph nodes.
Furthermore, they showed that nasal boosting induces IL-
2 producing T-cells, antigen-specific IgG and IgA produc-
tion and antigen-specific B memory lymphocytes. To fur-
ther characterise T-cell proliferation, mathematical models
were used and it was observed that following nasal
immunization, the probability of T-cells entering division
is higher and the time of the first division is faster com-
pared to vaginal immunization. Together, these results
provide additional information on mucosal vaccination
strategies.
The priming of T-cells is a critical event that influences
the type and magnitude of immune responses. Further
data from Medaglini’s group, presented by Fabio Fiorino,
evaluated primary CD4+ and CD8+ T-cell activation
induced by different mucosal routes of immunization.
Mice vaginally and nasally immunized with OVA+CpG
were studied for clonal expansion, activation and migra-
tion markers at different time points. Both vaginal and
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nasal routes of immunization induced high T-cell clonal
expansion in the respective draining lymph nodes by day
three after vaccination, whilst at day 5, primed T-cells
were also detected in distal lymph nodes and in the spleen,
with higher percentages detected following the nasal route
immunization. The proliferating T-cells were activated
and acquired migration properties as indicated by the
modulation of CD44, CD45RB and CD62L.
Neutralizing antibodies
HIV-2 is a somewhat understudied virus with a lower
pathogenicity and transmission rate than HIV-1. Gulsen
Özkaya Sahin and Marianne Jansson from Lund University
in Sweden demonstrated that the breadth and potency of
neutralizing activity in plasma differ between HIV-1 and
HIV-2 infected individuals. Plasma from HIV-2 patients
was shown to neutralize HIV-2 isolates at a high frequency,
whereas plasma from HIV-1 patients had much lower
intratype neutralizing activity against HIV-1 isolates. The
intratype neutralizing activity correlated with viral load in
patients infected with HIV-1 but not with HIV-2. Hence
the neutralizing activity in HIV-2 infection does not seem
to require high levels of antigen stimulation, whereas this
is more important in HIV-1 infection. Jansson concluded
that the viral structure of HIV-2 may promote a more po-
tent humoral immune response and/or HIV-2 itself may
be more neutralization sensitive than HIV-1.
Stefania Dispinseri (San Raffaele Scientific Institute)
presented data from paediatric infections, correlating
disease progression with neutralizing responses. HIV-1
infected children with slow disease progression devel-
oped an increasing breadth of neutralizing response over
time, whereas fast-progressing children did not.
A similar study, conducted by Katharina Raue, a stu-
dent from the German Primate Center, analysed the im-
mune responses of infected rhesus monkeys, grouped
into controllers or progressors. Animals controlling the
infection demonstrated higher immune response than
progressors, both humoral and cellular, and the response
was directed against Gag proteins and not Envelope.
Not all patients develop broadly neutralizing anti-
bodies; in fact, only 10-30% of HIV-1 infected patients
possess antibodies with a strong cross-reactive neutraliz-
ing activity and less than 1% have broadly neutralizing
antibodies. Zelda Euler from the University of Amster-
dam performed a genome-wide association study, to
learn more about which genetic markers are involved in
the development of antibodies with broadly neutralizing
activity. The study included 335 HIV-infected men who
have sex with men from the Amsterdam Cohort with
known neutralizing activity of their sera. Single nucleo-
tide polymorphisms (SNP), in the major histocompatibil-
ity complex gene region, close to MICA and HCP5
genes on chromosome 6, were found to associate with
broadly neutralizing activity. HCP5 encodes HLA com-
plex protein 5, and has previously been associated with
viral load and disease progression in HIV infected indivi-
duals [28,29]. None of the identified SNPs which were
associated with broadly neutralizing activity were asso-
ciated with the clinical course of disease progression. In
addition, the association between SNPs or broadly neu-
tralizing activity of antibodies was not related to viral
load or CD4+ T-cell count at viral load set-point. Al-
though this finding is remarkable, its application to our
understanding of the factors modulating the mounting
of an effective immune response is not yet clear.
Marie Borggren, from the University of Lund, com-
pared how CCR5 and CxCR4-using HIV-1 evolve during
end-stage disease and how the immune responses correl-
ate with the evolution. The Env proteins of end-stage
viruses were often more positively charged and had
fewer glycans than virus from the chronic stage of dis-
ease. End-stage R5 viruses were shown to use the trans-
infection route from DC to T-cells less efficiently, which
might be due to loss of a specific glycan in gp120.
David Reinhart (Polymun and University of Natural
Resources and Life Sciences, Vienna) discussed the switch-
ing of the isotypes of anti-HIV-1 IgG antibodies 3D6 and
4B3 recognizing the ectodomain of gp41 to an IgA isotype
and their expression in CHO cells in serum-free medium
as dimeric IgA. The purification scheme mainly relies on
IgA affinity chromatography, using VHH ligands. Unlike
previously published protocols, the purification schedule
can be used for any IgA irrespective of alpha heavy chains,
light chains and their subtypes [30]. These new reagents
will allow the study of the influence of antibody isotype on
their function with respect to antiviral activity against HIV.
Studies are pending to investigate the potential role of IgA
during viral exposure at the mucosa.
Enas Sheik-Khalil (University of Lund) described the de-
velopment of an image-based high-throughput as well as
high-content HIV neutralization assay. The assay is based
on a plaque reduction assay along with a specialized image
analysis tool tailored to analyse neutralization. An add-
itional parameter, mean plaque area, enables the detection
of virus fusogenicity to characterize the duration in vitro
of neutralization. A decreased plaque size may indicate
avidity of neutralizing antibodies. The assay demonstrated
equal or higher sensitivity compared to conventional
neutralization assays.
Eliciting antibodies
Eliciting new type of antibodies and defining novel epi-
topes will be critical for future vaccine development.
Mark Hassell et al. (NIBSC) have produced novel C clade
specific antibodies by priming mice with plasmid DNA
encoding either CN54 or ZM96 gp140 genes, followed by
a CN54 trimeric gp140 boost, all of subtype C. Applying
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the trimeric immunogens, 18 HIV-specific antibodies were
successfully generated. However, no novel epitopes were
defined. Although all isolated antibodies bound CN54,
none were able to recognise and neutralise epitopes that
are specific for the trimeric envelope structure.
Another approach to elicit novel antibodies, presented
by Pierpaolo Racchiolli et al. (University of Verona), estab-
lished new anti-HIV-1 antibodies by immunizing mice
with CHO cells expressing gp120/gp41 and CHO cells
expressing CD4 and CCR5 to generate fusion intermediate
structures of the HIV envelope. One hybridoma clone,
10 F12, which showed the highest HIV-1 neutralization
activity and lowest cell reactivity, was further investigated
and stably produced in CHO cells as a chimeric antibody.
Hybridoma and chimeric antibodies both neutralized sev-
eral HIV viruses.
Other roles for antibodies
HIV infection can be inhibited by both neutralizing and
non-neutralizing antibodies via the Fc receptor. Infection
of myeloid dendritic cells, mDC, has been shown to be
inhibited using both types of antibody. In contrast,
Alexandre Lederle, a student from University of Stras-
bourg, demonstrated that infection of plasmacytoid den-
dritic cells, pDC, can be inhibited only by neutralizing
antibodies, not by non-neutralizing antibodies, despite
the expression of Fc receptors on the surface of pDC.
As discussed previously, transmission of HIV-1 via mu-
cosal tissues during sexual intercourse globally represents
the main route of infection. Immature dendritic cells res-
ide in the genital mucosal tissues and are believed to be
among the first cells to be in contact with HIV. An
infected DC may act as a “Trojan horse” for HIV and fur-
ther transmit viruses to primary CD4+ T lymphocytes.
Antibodies that inhibit such viral transfer could prevent
HIV infection. Bin Su from the University of Strasbourg
addressed this hypothesis and demonstrated that neutral-
izing antibodies could efficiently inhibit the transfer of
several R5 HIV-1 strains from primary DCs to autologous
CD4+ T lymphocytes. Furthermore, he showed that neu-
tralizing as well as non-neutralizing antibodies could de-
crease HIV-1 replication in DCs. Induction of both types
of antibodies directly at mucosal sites may thus be benefi-
cial when designing a future vaccine.
Besides neutralization, HIV-specific antibodies could
thus have an impact on protection against HIV-1 trans-
mission in several ways. Such HIV-specific antibodies
could target not only free virions, but also infected cells,
as well as the HIV transfer from infected cells to other
cells. In order to understand the contribution of anti-
bodies induced against these targets and especially the role
of Fc-mediated protection, Marina Biedma from the Uni-
versity of Strasbourg investigated several inhibitory func-
tions of anti-HIV IgGs. It was found that non-neutralizing
inhibitory antibodies (NNIAbs) could mediate inhibitory
activities such as ADCC or phagocytosis. Indeed, it was
demonstrated that NNIAbs such as 4B3 and 246D were
highly efficient in capturing free virions when compared
to neutralizing antibody 2G12, 4E10 or 2F5. Furthermore,
NNIAbs 4B3 and 246D revealed Fc-mediated inhibitory
activities on viral replication in macrophages and DCs
similar to some neutralizing antibody. When applied lo-
cally at the vaginal site of macaques, these NNIAbs were
able to significantly decrease the peak viral load following
vaginal experimental challenge with SHIV SF162P3. These
results suggest that NNIAbs may be important in control-
ling viral infections.
In addition to broadly neutralizing antibodies, other tar-
gets for antibodies with alternative antiviral function are
being explored. Donato Zipeto from the University of Ver-
ona described the identification of one such new target by
unravelling the association between HLA-C and gp120.
Using bimolecular fluorescence complementation analysis,
it was shown that HLA-C competes for binding between
β2m and gp120. Furthermore, association of gp120 with
HLA-C happens early in the endoplasmic reticulum and
continues during passage through the Golgi apparatus and
early endosomes, until presentation at the cell membrane.
It was found that HLA-C specifically incorporates into
HIV-1 envelopes and increases viral infectivity by increas-
ing viral envelope fusion with R5 and X4 HIV strains. A
compound or antibody that could disturb this association
might decrease viral infectivity. Furthermore, antibody to
HLA-C displayed on the virusor virus-infected cell surface
might participate in ADCC.
Innate immunity against HIV
In a setting where ongoing attempts to develop an HIV-1
vaccine face significant challenges, investigation of innate
immune factors and the host response to infection are
crucial for the development of novel prophylactic strat-
egies against HIV/AIDS. Innate responses not only influ-
ence mucosal transmission and establishment of initial
infection foci, but may also have an impact on the subse-
quent level of ongoing viral replication and rate of disease
progression [31]. Studies were presented to explain the
contributions made by components of the host innate re-
sponse to HIV acquisition and spread versus its control.
Magarita Bofill (IrsiCaixa, Barcelona) has previously
described that co-stimulation of mononcytes with IL-12
and IL-18 triggers the survival and differentiation of
monocytes to macrophages, important players in innate
immunity [32]. As an advance on this work she demon-
strated that the treatment of differentiated macrophages
but not monocytes with IL-12 and IL-18 induces pro-
duction of IFN-γ in an antigen-independent manner.
Absence of proviral or integrated DNA in target macro-
phages identified the inhibitory effects of IL-12 and IL-
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18 as entry events. Furthermore, IL-12 and IL-18
induced Apobec3G up-regulation in these target cells.
Interferon (IFN)-induced intracellular antiviral proteins,
referred to as restriction factors, are capable of interfering
with retroviral replication at various steps of the viral life-
cycle. Elisa Vicenzi’s group (San Raffaele Scientific Insti-
tute) has exploited cell clones isolated from the U937 pro-
monocytic cell line, either permissive or non-permissive
for HIV-1 replication. Data revealed that among known
HIV-1 restriction factors, the IFN-inducible Tripartite
motif-containing protein 22 (TRIM22) was the only factor
constitutively expressed in non-permissive but absent in
permissive U937 cells. Conversely, stable knock-down of
TRIM22 rescued the non-permissive cell line, while over-
expression of TRIM22 in a permissive cell line inhibited
HIV-1 replication. A similar inhibitory effect of TRIM22
was confirmed in human A301 T-cells. Most likely, nu-
clear TRIM22 impairs HIV-LTR driven transcription in a
Tat- and NF-κB-independent manner [33].
Adjuvants
Specific adjuvant formulations triggering innate immune
signalling pathways can improve the potency and quality
of adaptive immune responses. Therefore, many studies
are focusing on the development of novel adjuvants that
might increase the immunogenicity of HIV-1 antigens.
Annette Sköld (Karolinska Institutet) presented a poster
on the use of single-stranded DNA oligonucleotides
(ssDNA ODNs) as an inhibitor of detrimental TLR3
responses. Results showed that the addition of ssDNA
ODNs inhibited the TLR3-triggered cytokine release and
maturation of human DCs. In addition, ssDNA ODNs
blocked TLR3-mediated release of pro-inflammatory cyto-
kines in the airways of cynomolgus macaques. In summary,
while the use of ssDNA ODN might open novel perspec-
tives for clinical treatment of TLR3-mediated inflammatory
disorders, it was clear that combining ssDNA ODN with
TLR3 agonists may be detrimental for the efficient induc-
tion of immune responses.
In work presented by Quentin Sattentau (University of
Oxford), the nucleic acid transfection reagent polyethyle-
neimine (PEI) was shown to exhibit potent mucosal adju-
vant properties. Intranasal administration of the influenza
HA antigen, adjuvanted with PEI, protected mice against
viral infection and disease. Moreover, in the induction of
protective responses, PEI was superior to other known mu-
cosal adjuvants, including CpG. Similar results were
obtained for herpes simplex virus 2 (HSV-2) gD and HIV-1
gp140 antigens. It was shown that PEI forms complexes
with antigens, thereby targeting DCs. Indeed, such particu-
late antigen systems are similar in size to microorganisms,
and are consequently efficiently taken up by phagocytic
cells, including DCs. In addition, PEI was shown to activate
innate immune responses, including inflammasome- and
MyD88-dependent pathways.
HIV/SIV pathogenesis and disease progression
Correlates of pathogenicity
Based on previous observations that a high frequency of
adenosine nucleotide in HIV/SIV RNA correlates with the
pathogenicity of a lentivirus, a study presented by Frederic
Tangy (Institut Pasteur) focused on the effect of the viral
A/C/G/T nucleotide ratio on stimulation of innate im-
mune responses. Synthetic SIVs genomes were designed
without modifying regulatory elements or sequences of
amino acids. The first SIV was subjected to codon changes
of gag and pol genomic regions, which resulted in a dra-
matic decrease in replicative capacity. The second SIV
harboured only a pol optimized gene, which resulted in a
reduced ability to stimulate type-I interferon in vitro in
cellular assays. Nucleotide patterns (without changed
amino acid patterns) may thus play a role in the induction
of innate immunity and in virulence.
A EUROPRISE student Aneela Javed (German Primate
Center) investigated factors correlated with CD8+ T-cell
Non-Cytolytic Antiviral Activity (NCAA) in SIV-infected
rhesus macaques. NCAA is associated with reduced trans-
mission of HIV and slow disease progression. NCAA+and
NCAA- animals were identified using an in vitro viral in-
hibition test. Differentially expressed genes in CD8+ T-cells
from NCAA+and NCAA- animals were investigated using
microarrays. FAM26F, translating a membrane-bound pro-
tein with undefined function, was identified as a candidate
gene. Furthermore, the expression of FAM26F is negatively
correlated with viral load, while positively correlated with
the expression of two cytokines, IP-10 and MX. Further
studies in humans are ongoing.
T-cells
Not all individuals have the same T-cell profile, and co-
infection with HIV and other viruses, bacteria or parasites
may influence the target T-cell pool for HIV. Understand-
ing the co-infection responses and the consequence for
the HIV infection could affect individualized treatment.
William Paxton from the University of Amsterdam com-
pared the mycobacterium tuberculosis (MTB)- and cyto-
megalovirus (CMV)-specific CD4 T-cell responses in
patients co-infected with HIV. His results demonstrate
that the CD4 T-cell population is skewed in these patients,
with a persistent CMV-specific T-cell response but a
MTB-specific response that was rapidly depleted. The
CMV-specific CD4 T-cells had a mature phenotype, with
high MIP-1β and low IL-2 producing cells. In contrast,
the MTB-specific CD4 T-cells were less mature, with
more IL-2 production and less MIP-1β. These findings
confirm that HIV preferentially infects IL-2 producing T-
cells, and that MIP-1β producing cells are more resistant.
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B-cells
Nicolas Ruffin from the Karolinska Institutet investigated
the effect of HIV infection on the B-cell compartment of
HIV-infected patients. He found that the levels of sCD14,
a marker of microbial translocation, correlated with B-cell
activation and loss of resting memory B-cells. sCD14 was
associated with higher IL-21R expression on resting mem-
ory B-cells and the B-cells bearing IL-21R were shown to
be more susceptible to apoptosis. This finding provides an
important insight into how the humoral arm of the im-
mune system may be affected by the microbial transloca-
tion that occurs during HIV-1 infection.
Simone Pensieroso (San Raffaele Scientific Institute)
examined the hypothesis that highly efficient long-term
antiretroviral therapy could quantitatively restore all B-cell
subsets. In particular he examined resting memory B-cells,
which are responsible for secondary immune responses
and are severely depleted in HIV-infection. After failure of
previous therapies, 30 HIV-1 infected multi-drug experi-
enced patients were treated with Highly Active Antiretro-
viral Therapy (HAART including Raltegravir) and followed
for 144 weeks. 72 age-matched uninfected individuals were
used as healthy controls. An effective Raltegravir-including
regimen was shown to restore all B-cell subpopulations
with the exception of the resting memory B-cell subset
when monitored for up to three years. A longer follow-up
study might determine whether resting memory B-cells
need even more time to recover.
New methods and reagents
Measurement of immune responses
One of the objectives of the EUROPRISE consortium
has always been to develop new techniques, assays and
standard reagents and make them available to research-
ers around the world to help accelerate research on HIV
vaccines and microbicides.
A new assay developed by Mabtech with support from
EUROPRISE is the FluoroSpot assay, which is based on
the same principle as the well-known ELISpot assay. The
FluoroSpot assay is characterized by high sensitivity and
specificity and can be used to analyse simultaneous secre-
tion of cytokines by T-cells. It also allows the quantifica-
tion of singly and dually secreting cells. Clearly, this can
provide important information about the quality of a spe-
cific T-cell response. So far, combinations of IFN-γ /IL-2,
IFN-γ /IL-5, IFN-γ /IL-13, and IFN-γ /IL-17A have been
developed. Furthermore, it is possible to detect IgG and
IgA secreted by B-cells in a single well and analysis can be
performed on mice, monkey and human cells.
JPT Peptide Technology, a company in Germany, pre-
sented their technology platform for peptide microarrays.
They have generated a versatile peptide library spanning
the immunogenic fractions of the HIV proteome with high
coverage across viral clades. JPT have been successful in
generating overlapping peptide sets representing all im-
munogenic regions of target HIV proteins. The final library
of 5572 different 15-mer peptides achieves coverage of 86%
of all 3578 M-group and recombinant sequences of p24 as
well as coverage of 50% of the published 2248 sequences of
gp160. A major advantage of this library design is the abil-
ity to condense and cover the immense complexity of the
immunogenic domains of the HIV proteome with only
5572 overlapping peptides that can be accommodated on a
single high-density peptide microarray for clinical HIV
research. These peptide microarrays have several applica-
tions, such as biomarker identification, vaccine target iden-
tification, immuno-monitoring, mapping B-cell responses,
and profiling of enzymatic activity. Monitoring the anti-
body response in detail before and after vaccination in pa-
tient samples is crucial. In this context, the peptide
microarray, which gives insights into the antigen-antibody
interaction on the sub-protein level, may complement
other assays which rely on the entire antigen. Nevertheless,
the technology is restricted to the extent that it can map
only linear and not conformational epitopes.
Reagents
The Division of Retrovirology at the NIBSC in the UK
produces a variety of biological standards and reference
materials designed as quality controls for HIV diagnostic
(serological) assays and nucleic acid-based amplification
techniques. The HIV-1 and HIV-2 Internal standards (IS)
developed by NIBSC have been used to standardize both
commercial and in-house assays. NIBSC has also devel-
oped a first genotype panel containing genotypes A-H, as
well as HIV-1 working reagents calibrated against internal
standards to support serology-based diagnostic assays. A
selection of recently transmitted subtypes and subgroups
of HIV-1 strains has been assembled to create a panel with
a great variety of viral stocks. The viral isolates were col-
lected from HIV-1 infected patients and expanded in
PHA stimulated PBMCs, whereafter they were character-
ized using RT-PCR and phylogeny. The stocks are held by
NIBSC and are available to all HIV researchers.
The Center For AIDS Reagents (CFAR) at NIBSC has
been able to support HIV/AIDS research through the
supply of reagents to scientists in Europe and worldwide.
With the help of 173 novel materials provided by the
EUROPRISE collaborators, CFAR now has a repository of
over 6000 reagents. They have also successfully produced
novel, lyophilized cell preparations for detecting and quan-
tifying CMI assays. The availability of such useful materials
is a legacy of success for the EUROPRISE group.
Concluding remarks
The fifth EUROPRISE Network annual conference was
held in Prague in November 2011 in an atmosphere of
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optimism. Imaginative and novel strategies to be used in
HIV prophylaxis and intervention were discussed.
The scientists involved in this Network of Excellence
have participated in over 200 multi-author papers, weekly
bulletins have been provided within and outside the net-
work, and HIV/AIDS reagents have been provided to col-
leagues worldwide. The Network´s extremely successful
students have bound the research groups together, formed
networks of their own and brought an immeasurable feel-
ing of collaboration, sharing of ideas and positive aspects
of future research collaboration to the Network. Such
integrated science will permit continued developmental
research from discovery to clinical trials, some of which
are described in this review.
The co-usage of vaccines and microbicides is unique;
the Network has brought forward research in this area
and is now also starting preclinical and clinical trials
with the aim of combining the two. The meeting in
Prague was focused on collaborative work between part-
ners, in particular scientific work performed and pre-
sented by the Network’s PhD students. The abilities of
students to perform and present up-to-date science
promise a bright future for the next generation of HIV
researchers in Europe.
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